Friday, July 10, 2026

pharma · Glioblastoma · Unresectable or metastatic soft tissue sarcoma

Philogen

Philogen S.p.A is a pharma organization headquartered in SIENA, IT. Primary therapeutic focus areas include Glioblastoma, Unresectable or metastatic soft tissue sarcoma, Cutaneous Squamous Cell Carcinoma, locally advance

Loc. Bellaria, 35, Sovicille, SIENA 53018, IT HQ
1996 Founded
180 Employees
EMA registrant Type
Company details
Status
Public
HQ
Loc. Bellaria, 35, Sovicille, SIENA 53018, IT
Founded
1996
Employees
180
Programs
18
Drugs
29
Patents
0

Quick answer

Philogen S.p.A is a pharma organization headquartered in SIENA, IT. Primary therapeutic focus areas include Glioblastoma, Unresectable or metastatic soft tissue sarcoma, Cutaneous Squamous Cell Carcinoma, locally advanced basal cell carcinoma patients. NovaPharmaNews links 18 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 2 (9), phase 1 (7), phase 3 (2).

Company snapshot

Philogen is a Swiss-Italian integrated biotechnology company founded in 1996, with the mission to develop innovative biopharmaceuticals for the treatment of angiogenesis-related disorders. Angiogenesis, i.e. the formation of new blood vessels, is a characteristic feature of many severe pathologies such as cancer, rheumatoid arthritis and age-related macular degeneration. The company has been a pio

  • 18 active pipeline program(s) linked via ClinicalTrials.gov.
  • 18 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Philogen. Not investment advice.

Lead pipeline drugs

Active clinical programs

  • Darleukin, Fibromun Malignant melanoma of the skin in patients with locally advanced and fully resectable melanoma with/without prior therapy and presence of injectable cutaneous and/or subcutaneous or nodal lesions
    Phase 3
  • PH-L19TNFDOX2-03/16 Unresectable or metastatic soft tissue sarcoma
    Phase 3
  • Darleukin, Fibromun locally advanced basal cell carcinoma patients
    Phase 2
  • Darleukin, Fibromun Patients with high-risk, locally advanced (non-metastatic, node negative, single or multifocal), Basal Cell Carcinoma (BCC) or cutaneous Squamous Cell Carcinoma (cSCC) amenable to intratumoral injection, not eligible to surgery or radiation therapy according to the evaluation of a local interdisciplinary tumor board or who refuse surgery or radiation therapy and for whom a histological evaluation is available according to international guidelines.
    Phase 2

Momentum

Proprietary activity score for Philogen.

0 /100 +0 vs 30 days ago

Signal breakdown

  • Clinical trials 0 30d
  • Nova articles 0 30d
  • Patents filed 0 30d
  • FDA actions 0 30d
  • SEC filings 0 30d
  • Conference presentations 0 90d
  • Pipeline advances 0 30d

Recent activity

Latest pipeline, patent, and corporate events for Philogen.

  1. Clinical update

    PH-L19TNFDOX2-03/16 — Phase 3

  2. Clinical update

    PH-F8IL10INTRA-03/24 — Phase 1

  3. Clinical update

    PH-CAIXGA-02/24 — Phase 1

  4. Clinical update

    PH-ACP3GA-03/25 — Phase 1

  5. Clinical update

    PH-ACP3GA-01/24 — Phase 1

View all clinical trial activity →

Quick answers

Common questions about this sponsor — for analysts and search.

  • What is Philogen?

    Philogen S.p.A is a pharma organization headquartered in SIENA, IT. Primary therapeutic focus areas include Glioblastoma, Unresectable or metastatic soft tissue sarcoma, Cutaneous Squamous Cell Carcinoma, locally advanced basal cell carcinoma patients. NovaPharmaNews links 18 cli

  • Is Philogen publicly traded?

    Philogen appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

  • What drugs does Philogen develop or market?

    We link 29 drug profile(s) where Philogen is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/philogen-s-p-a#company-drugs.

  • What are the latest developments for Philogen?

    In the last 12 months our linked public records show 18 trial program update(s) and 0 US patent grant(s) tied to this profile.

  • What therapeutic areas does Philogen focus on?

    Philogen focuses on Glioblastoma, Unresectable or metastatic soft tissue sarcoma, Cutaneous Squamous Cell Carcinoma based on our analysis of their pipeline programs and drug development activities.

Therapeutic focus

Therapeutic area distribution

Pipeline concentration by therapeutic area from linked clinical programs.

Programs by therapeutic area

Others
19
Oncology
7
Immunology
1